Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83 ... are available in more than 180 countries worldwide. Consumer Health Company (Opella) (Sold-Out entity) Headquartered in France ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion ... rising income levels, and greater health and ...

French drugmaker Sanofi's confirmation that it will sell a controlling stake in its consumer health unit to a US ... volume for Opella's sensitive products in France," Armand added, including ...

Sanofi has entered exclusive talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of the former’s consumer health business ... most paracetamol products are referred ...

Fitch Solutions has predicted that the naira would slide to as low as N1,993 per dollar in 2028, severely impacting Nigeria’s ...